Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
PhaseV logo — Adaptive. Causal. Intuitive.

PhaseV

Adaptive. Causal. Intuitive.

Founded 2023 United States Cambridge, United States 61 employees Series A Total: $65.00M

General Information

Company Name PhaseV
Founded Year 2023
Location United States Cambridge, United States
Employees 61
Funding Stage Series A
Business Model B2B, SaaS
Revenue Model Subscription, Service Fee, Usage Based
Social

BounceWatch is an independent company data service, not affiliated with PhaseV. To contact PhaseV, visit phasevtrials.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does PhaseV compare?

A PDF of PhaseV and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting PhaseV soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About PhaseV

PhaseV, founded in 2023 and headquartered in the United States, is making strides in transforming clinical development. This Boston-based technology company is known for its slogan: Adaptive. Causal. Intuitive. The firm offers an enterprise-ready AI/ML platform designed to expedite clinical decisions, minimize trial risks, and enhance portfolio efficiency.

Key innovations include the Trial Optimizer, which promises up to a 50% cost reduction, 40% fewer enrollment requirements, and a 30%+ increase in trial success probabilities. Their ClinOps Optimizer improves site selection by leveraging patient-level insights, while the Lifecycle Management module integrates causal evidence to guide portfolio decisions.

Recently securing a $50.00M Series A investment on 01 May 2025, with backing from prominent investors such as LionBird, Insight Partners, Viola Ventures, Accel, and Exor Ventures, PhaseV is well-positioned to optimize clinical development at every stage.

Business keywords: AI/ML Platform, Clinical Development, Trial Optimization, Cost Reduction, Enrollment Reduction, Timeline Shortening, Probability of Success Boost, Site Selection, Patient-Level Insights, Real-Time Dashboards, Portfolio Efficiency, Clinical Data Analysis, Adaptive Trial Design, Statistical Approaches, Lifecycle Management

Services & Products

ClinOps Optimizer
Trial Optimizer
Response Optimizer
Portfolio Optimizer
ML Early-Derived Endpoint Identification

Target Customers

Biopharma Sponsors Contract Research Organizations (CROs) Clinical Trial Teams Pharmaceutical Companies

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $50.00M 5
LionBird Insight Partners Viola Ventures
LionBird, Insight Partners +3
01 May 2025
Early VC $15.00M 3
LionBird Viola Ventures
LionBird, Viola Ventures +1
01 Oct 2023

PhaseV Alternatives & Competitors

View All Alternatives
PhaseV vs
Arine
Arine United States

Ensuring each patient is on the safest, most effective therapy for their unique health needs

Series B
201 employees
Biotechnology, Health Care
PhaseV vs
ThingsAt
ThingsAt Australia

Technology agnostic and vendor independent, ThingsAt device management is the smarter way to manage...

14 employees
Information Technology
PhaseV vs
ServiceMesh
ServiceMesh

Empowering businesses with agile cloud control and cost-efficient IT service delivery.

Venture round
Cloud Infrastructure, Computing
View all alternatives

FAQ About PhaseV

Adaptive. Causal. Intuitive.
PhaseV was founded in 2023.
PhaseV is headquartered in Cambridge, United States.
PhaseV has a B2B and SaaS business model. Its revenue comes from Subscription, Service Fee and Usage Based.
PhaseV has approximately 61 employees.
PhaseV has completed 2 funding rounds, raising a total of $65.00M. The latest funding stage is Series A.
PhaseV offers: ClinOps Optimizer, Trial Optimizer, Response Optimizer, Portfolio Optimizer, ML Early-Derived Endpoint Identification.
Top alternatives and competitors to PhaseV include Arine, ThingsAt, ServiceMesh. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
PhaseV and Arine are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for PhaseV, https://bouncewatch.com/company/phasev, updated 4 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes